ArticleGynecologic oncology2025
The impact of antibiotics, proton pump inhibitors, H2-receptor antagonists, and steroids on survival in ovarian cancer patients receiving PARP inhibitor therapy.
Article in Gynecologic oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
objectiveAntibiotics (ABX) have been linked to reduced survival in ovarian cancer (OC) when administered before or during platinum-based chemotherapy. This study evaluates the impact of ABX, proton pump inhibitors (PPI), H2-receptor antagonists (H2RA), and steroids on progression-free survival (PFS) in OC patients receiving poly-ADP-ribose polymerase inhibitors (PARPi).
methodsThis retrospective study examined OC patients who used ABX, PPI, H2RA, or steroids before or during PARPi therapy. Demographics, clinicopathologic characteristics, and treatment outcomes were analyzed. Cox proportional hazards models assessed risk factors for PFS, and Kaplan-Meier analysis with log-rank testing evaluated survival differences based on ABX use.
resultsAmong 237 patients treated with 269 PARPi regimens, most received PARPi in the recurrent setting (79.6 %). At the time of PARPi therapy, 21.6 % used ABX, 15.6 % PPI, 11.2 % H2RA, and 63.9 % steroids. Patients with HRP/unknown status had significantly worse median PFS than those with BRCA-mutated/HRD (6 vs. 11 months; p < 0.001). ABX use correlated with improved median PFS (10 vs. 7 months; p = 0.049) but lost significance in multivariate analysis. PPI, H2RA, and steroids had no impact on PFS.
conclusionIn this retrospective analysis, concurrent medications were not associated with worsened survival outcomes in OC patients receiving PARPi. Further, while ABX use during PARPi therapy was associated with improved survival this was not significant after adjusting for confounders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.